
Novo Nordisk is forging a future beyond the patent expiration for its lucrative molecule semaglutide, which is behind the company’s best-selling drug by some distance, diabetes treatment Ozempic, which sold for DKK 33.7bn (USD 5.2bn) in 2021 alone.
With the goal of securing a post-semaglutide future, Novo Nordisk is searching far and wide – not just for one candidate but for a long list of new drugs to compensate for the enormous gap that will be left once the semaglutide patent runs out.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app